Clinical Trials

• No kidney disease (eGFR is greater than 45)
• Does not have severe claustrophobia

Primary Inclusion Criteria:

• Subject has severe (Grade III or greater per the ASE criteria, which includes severitygrades of 3+ and 4+) primary MR (mixed etiology is acceptable provided theprincipal mechanism of action is a degenerative mitral valve) as assessed bythe ECL.

• Subject is at least 75 years of age

Primary Inclusion Criteria:

• Patients ≥ 18 years old
• Patients with paroxysmal or persistent AF undergoing routine pulmonary vein isolation (PVI)
• Patients undergoing a cardiac MRI prior to AF ablation

Primary Exclusion Criteria:

• Contraindication to MRI
• Abnormal renal function (eGFR < 60 mL/min/1.73 m2)

• Completion of a Cytokinetics study investigating CK-3773274. If unable to complete due to circumstances not related to compliance or safety, Medical Monitor may review and determine eligibility.
• LVEF ≥ 55%

• Failing aortic bioprosthetic valve demonstrating ≥ moderate stenosis and/or ≥ moderate insufficiency
• Bioprosthetic valve size suitable for SAPIEN X4 THV based on computed tomography angiography (CTA) analysis
• NYHA functional class ≥ II

• Chronic symptomatic heart failure (HF)
• Ongoing stable GDMT HF management and management of comorbidities according to the 2022 ACC/AHA Guidelines for the Management of Heart Failure.

• Documented history of symptomatic or asymptomatic paroxysmal or persistent AF
• CHA2DS2-VASC score of 1-4 without prior stroke or TIA
• Participant is on a DOAC at time of screening

• PE symptom(s) duration ≤ 14 days from index procedure
• PE diagnosis ≤ 48 hours prior to index procedure
• CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery based on Investigator determination)
• CTA evidence of dilated RV with an RV/LV ratio of ≥ 0.9 at baseline based on Investigator determination
• Systolic blood pressure ≥ 90 mmHg without need for vasopressors (initial SBP may be ≥ 80 mmHg if the pressure recovers to ≥ 90 mmHg with intravenous fluids prior to index procedure)
• Stable heart rate < 130 BPM prior to index procedure

Ambulatory with an age of 22-85 years at time of enrollment

Heart Failure with EF ≥ 40% (by TTE within last 3 months)

NYHA Class II or III

• Patient with HF who signed the informed consent forms accepting his/her data collection and tele transmission
• Patient Presenting “acute heart failure event"
• Patient with blood test data ([B-type natriuretic peptide (BNP) or N-Terminal pro B type natriuretic peptide (NT-proBNP) at the acute HF event
• Patient with HF class III and IV according to the New York Heart Association functional classification

Diagnosis of ATTR-CM

Medical history of HF

Treatment for HF/ATTR-CM is optimized and symptoms are clinically stable

• NYHA functional class II or III
• A diagnosis of HCM
• For oHCM, LVOT peak gradient ≥ 30 mm Hg at rest OR during a Valsalva maneuver at Screening visit
• For nHCM, LVOT peak gradient < 30 mm Hg at rest AND during a Valsalva maneuver at Screening visit
• Screening LVEF ≥ 50%. For patients on a cardiac myosin inhibitor, the Screening LVEF must be ≥ 55%

• Multivessel or left main CAD is present for which revascularization is intended and for which there is equipoise between CABG and PCI according to local Heart Team assessment

• Patient has a history of heart failure
• Patient has a left ventricular ejection fraction measured within 6 months of study enrollment recorded in the medical record
• Patient is scheduled to undergo a right heart catheterization (RHC) procedure per standard of care, which will include direct PCWP and PAP measurement
• Patient is willing to wear the CardioTag device during their RHC procedure

• Is suspected of having cardiac amyloidosis and is undergoing or will undergo a diagnostic evaluation for cardiac amyloidosis (e.g., echocardiography, CMR, bone avid tracer cardiac SPECT, extracardiac or endomyocardial biopsy, etc.). Participants can be enrolled before or during their diagnostic evaluation for cardiac amyloidosis.
• Able to undergo PET/CT imaging as part of the study, including ability to lie supine for approximately 1 hour.